ARCHIVES

Novel Agents Promise Relief From Hematologic Side Effects

This article is from The Cancer Letter archive.

Vol. 24 No. 7 | July 27, 2001

Download PDF Visit The Full Archive

Related Articles

FDA Adopts Plan For Drug Approval After Phase 2; Chabner Unconvinced

November 4, 1988

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

June 27, 2014

Cancer Policy: EMFs “Possible” Carcinogen, Panel Says; Plans Public Hearings

August 7, 1998

Take Program Direction Away From CCIRC, Form New Group for Clinical Trials, Conferees Suggest

June 6, 1975

MD Anderson Survey Shows Faculty Dissatisfaction with Top Leaders

May 23, 2014

CTEP Director Friedman Adds To Article On Minority Initiative

March 23, 1990